Autoimmune diseases can be accompanied by presence of various antiphospholipid antibodies (aPL). The laboratory criteria of antiphospholipid syndrome are based on detection of anticardiolipin, lupus anticoagulant or to antib2-glycoprotein I but currently a significance of other multiple aPL is being discussed. Because of their vascular and neuroinflammatory effect aPL, if being transplacentally transferred, might inflict damage in developing organism.
Introduction
Autoimmune diseases (AD) affect 5% of the population with a high prevalence in women of childbearing age and, in some cases, associated with the presence of various antiphospholipid antibodies (aPL). Some aPL isotypes can cross the placental barrier into the fetus and cause antibody-mediated harm. The sustained presence of aPL may influence several systems and affect further development of the exposed child. 1, 2 Objective The objective of this study was to determine the presence and kinetics of eight aPL (anti-b2-glycoprotein I (ab2GPI), anticardiolipin (aCL), antiphosphatidylserine, antiphosphatidylinositol, antiphosphatidylethanolamine, antiphosphatidylglycerol, antiphosphatidic acid and anti-annexin V) in mothers with a known diagnosis of AD and their offspring just after birth and then at the age of six months and to evaluate the health status and development of the children.
Patients and methods
This prospective study included 38 women: 17 with primary antiphospholipid syndrome (PAPS) and 21 women with other autoimmune diseases (systemic lupus erythematosus, Sjogren's syndrome, autoimmune thyroiditis, multiple sclerosis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, autoimmune haemolytic anaemia, Crohn's disease), all positive for aPL. Also included were 39 children (including a pair of twins) born to the above women between January 2009 and April 2010 in the Perinatology Centre in Pilsen, Czech Republic. The control group consisted of 30 mothers without AD and their 30 healthy singletons.
The observed parameters in the women studied were: age, education, marital status, mode of delivery, pharmacotherapy and type of aPL present. Evaluation of aPL in women was performed during gestation and immediately after delivery. Antiannexin V, ab2GPI and aCL were tested using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Antiphosphatidylserine, antiphosphatidylinositol, antiphosphatidylethanolamine, antiphosphatidylglycerol and antiphosphatidic acid antibodies were tested by an in-house (ELISA) using purified phospholipids obtained from a commercial source (Sigma-Aldrich Corp., St. Louis, Missouri, USA). Cut-off levels were established as previously reported. 3 First blood sampling and testing in neonates were performed on third to fifth day of life with a second sampling an analysis conducted during the out-patient visit at six months of age. In children, we analysed the anthropometric data, the gestational age and postpartum adaptation, blood cell count, ultrasound of the brain and abdominal organs, the transient evoked otoacoustic emission test (OAE), an electrocardiogram (ECG) and the presence and type of aPL. At six months of age we re-examined for the persistence of antibodies and health status of aPL-positive children. Informed consent was obtained from the mothers and the experimental protocol was approved by the ethics committee.
Results
The mean age of 38 aPL-positive women was 32.8 years (23-40 years), 25 of them (65.8%) were married, eight (12.6%) single and one (2.6%) divorced. Most aPL-positive mothers had received secondary education (25 women; 65.8%), eight women (21.1%) higher education and five (13.2%) women primary education. Of all the women with primary APS, 13 (76.5%) were treated with low molecular weight heparin and four (23.5%) with anti-platelet therapy. Women with other AD were treated with corticosteroids in 57.1% of the cases whereas immunosuppressive drugs were used in 1%. Delivery by caesarean section was more frequent in mothers with AD than in the control group (55.3% vs. 26.6%, p < 0.005). The most frequently detected aPL in women were IgA anti b2 glycoprotein I (in 16/38; 42%), antiphosphatidylserine (in 11/38; 28.9%) and antiphosphatidylethanolamine (in 11/38; 28.9%).
In the neonatal group the incidence of prematurity (18.4%) and that of intrauterine growth retardation/adnate hypotrophy were higher than in the general European population (18.4% and 16.7%, respectively). 4, 5 Other anthropometric data of children showed no deviation in relation to their gestational age. The presence of aPL was found in 16 (41%) of the children included in study group. Mothers and children from the control group were aPL negative. IgG antiphosphatidylserine was the most frequent aPL present in children.
Overall, none of the children had cytopenia or pathological ECG findings. Mild pathological features in central nervous system ultrasound were found in 4% of children with no relevant difference between groups. An OAE test was normal in 85.7% of all cases with no differences between subgroups. No cases of neonatal thrombosis have been reported.
At six months aPL were detected in 6/16 (37.5%) of those children initially found to be aPL-positive, 7/22 (31.8%) children from aPL-positive mothers initially aPL-negative became positive and 2/30 (10%) children from healthy mothers also aPLnegative became positive (10%).
Conclusion
Preliminary results of the study showed aPL in 42.1% of neonates from aPL-positive mothers with AD. This prevalence decreases to 37.5% at six months. The occurrence of aPL-positivity at six months of age in originally negative offspring could be attributed to vaccination or food exposure. 1, 6 Psychomotor development of these children seems not to be affected. The follow-up study continues and will evaluate both groups of children at two years of age.
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